ArticleDiscover oncology2026
Development of a risk assessment model for the recurrence of high-grade squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasia in Chinese cohort.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo construct a sophisticated risk prediction model for the recurrence of high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN) after treatment. This model will help the early detection and focused screening of individuals at increased risk of dVIN.
methodsThe clinical data from 257 patients diagnosed with dVIN or HSIL were retrospectively reviewed. Patients were divided into two distinct cohorts: relapse (n = 60) and non-recurrence (n = 197). For robust model development, the dataset was methodically divided into two subsets: training (70% of cases) and validation (30% of cases). Logistic regression analysis was applied to identify key predictors. Subsequently, they were combined to construct a risk prediction model for post-treatment recurrence of HSIL and dVIN.
resultsUnivariate logistic regression analysis revealed that age, menopause, immunosuppression, HPV16 infection, histopathological characteristics, and positive surgical margins were positively correlated with recurrence risk. In contrast, low-risk HPV types exhibited a negative correlation with recurrence risk (all P < 0.05). Multivariable logistic regression analysis revealed that age, smoking history, immunosuppression, HPV16 infection, and histopathology were robustly associated with an increased recurrence risk (all P < 0.05). In the training dataset, the area under the receiver operating characteristic curve (AUC) was 0.793 (95% CI 0.77-0.880), accompanied by a median prediction success probability of 0.810. In the internal validation dataset, the AUC improved to 0.831 (95% CI 0.726-0.937). The Hosmer-Lemeshow goodness-of-fit test revealed acceptable model calibration for the training (P = 0.069) and internal validation (P = 0.086) sets. Calibration curves revealed trends remarkably consistent with the ideal curve, indicating commendable calibration. Furthermore, clinical decision curve analysis substantiated the net benefit of the model.
conclusionA prediction model including age, smoking history, immunosuppression, HPV16 infection, and histopathology exhibits good predictive performance for post-treatment recurrence of HSIL and dVIN. Our model can help clinicians assess recurrence risk, providing guidance for clinical consultations and enabling targeted follow-up and treatment plans for individuals at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.